Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Hua Medicine ( (HK:2552) ) is now available.
Hua Medicine has announced a change in the composition of its Remuneration Committee, appointing Mr. Yiu Leung Andy Cheung as a new member effective November 27, 2025. This appointment reflects the company’s ongoing efforts to strengthen its governance structure, potentially impacting its operational efficiency and stakeholder confidence.
The most recent analyst rating on (HK:2552) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Hua Medicine stock, see the HK:2552 Stock Forecast page.
More about Hua Medicine
Hua Medicine is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. It operates as a group with subsidiaries and is listed on the Hong Kong Stock Exchange under the stock code 2552.
Average Trading Volume: 6,785,616
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.15B
For a thorough assessment of 2552 stock, go to TipRanks’ Stock Analysis page.